[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
|
[2] |
MOLLAZADEH S, SAHEBKAR A, HADIZADEH F, et al. Structural and functional aspects of P-glycoprotein and its inhibitors[J]. Life Sci, 2018, 214: 118-123. doi: 10.1016/j.lfs.2018.10.048
|
[3] |
SUI J H, HE M M, YANG Y D, et al. Reversing P-glycoprotein-associated multidrug resistance of breast cancer by targeted acid-cleavable polysaccharide nanoparticles with lapatinib sensitization[J]. ACS Appl Mater Interfaces, 2020, 12(46): 51198-51211. doi: 10.1021/acsami.0c13986
|
[4] |
GUESTINI F, ONO K, MIYASHITA M, et al. Impact of Topoisomerase Ⅱα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy[J]. Breast Cancer Res Treat, 2019, 173(2): 275-288. doi: 10.1007/s10549-018-4985-6
|
[5] |
ZHANG H, ZHANG X Y, KANG X N, et al. LncRNA-SNHG7 enhances chemotherapy resistance and cell viability of breast cancer cells by regulating miR-186[J]. Cancer Manag Res, 2020, 12: 10163-10172. doi: 10.2147/CMAR.S270328
|
[6] |
叶柳青, 丁金旺, 张敏, 等. 同源盒基因转录反义RNA(HOTAIR)在乳腺癌临床诊疗中的研究进展[J]. 中华全科医学, 2018, 16(2): 286-290. doi: 10.16766/j.cnki.issn.1674-4152.000080YE L Q, DING J W, ZHANG M, et al. Research progress of HOX transcript antisense RNA in clinical diagnosis and treatment of breast cancer[J]. Chinese Journal of General Practice, 2018, 16(2): 286-290. doi: 10.16766/j.cnki.issn.1674-4152.000080
|
[7] |
YIN Y M, XIN Y, ZHANG F, et al. Overcoming ABCB1-mediated multidrug resistance by transcription factor BHLHE40[J]. Neoplasia, 2023, 39: 100891. DOI: 10.1016/j.neo.2023.100891.
|
[8] |
ZHANG L, LI Y D, HU C H, et al. CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells[J]. Mol Cancer, 2022, 21(1): 103. doi: 10.1186/s12943-022-01524-w
|
[9] |
柴冬亚. 重楼皂苷Ⅰ逆转人乳腺癌细胞耐药的作用及机制研究[D]. 昆明: 昆明医科大学, 2019.CHAI D Y. Reversal effect and mechanism of action of Polyphyllin I ondrug resistance of human breast cancer cells[D]. Kunming: Kunming Medical University, 2019.
|
[10] |
JACKSON J, LEUNG D, BURT H. The use of ultrasound to increase the uptake and cytotoxicity of dual taxane and P-glycoprotein inhibitor loaded, solid core nanoparticles in drug resistant cells[J]. UltrasonIcs, 2020, 101: 106033. DOI: 10.1016/j.ultras.2019.106033.
|
[11] |
NANAYAKKARA A K, FOLLIT C A, CHEN G, et al. Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells[J]. Sci Rep, 2018, 8(1): 967. doi: 10.1038/s41598-018-19325-x
|
[12] |
ZHONG P, CHEN X H, GUO R S, et al. Folic acid-modified nanoerythrocyte for codelivery of paclitaxel and tariquidar to overcome breast cancer multidrug resistance[J]. Mol Pharm, 2020, 17(4): 1114-1126. doi: 10.1021/acs.molpharmaceut.9b01148
|
[13] |
MAKUCH-KOCKA A, KOCKI J, BRZOZOWSKA A, et al. Analysis of changes in the expression of selected genes from the ABC family in patients with triple-negative breast cancer[J]. Int J Mol Sci, 2023, 24(2): 1257. doi: 10.3390/ijms24021257
|
[14] |
TO K K W, WU X, YIN C, et al. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes[J]. J Ethnopharmacol, 2017, 203: 110-119. doi: 10.1016/j.jep.2017.03.051
|
[15] |
詹东梅. 南蛇藤素对胃癌顺铂耐药SGC7901/DDP细胞的抑制作用及机制研究[D]. 扬州: 扬州大学, 2021.ZHAN D M. Inhibitory effect of celastrol on cisplatin resistant gastric cancer SGC7901/DDP cells and its mechanism[D]. Yangzhou: Yangzhou University, 2021.
|
[16] |
CHEN Y, ZHOU H Y, YANG S F, et al. Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer[J]. Cell Biochem Funct, 2021, 39(2): 277-286. doi: 10.1002/cbf.3577
|
[17] |
CUI J H, JIA J P. Natural COX-2 inhibitors as promising anti-inflammatory agents: an update[J]. Curr Med Chem, 2021, 28(18): 3622-3646. doi: 10.2174/0929867327999200917150939
|
[18] |
AJIYH A K, SUBRAMANI S, MANICKAM A H, et al. Chemotherapeutic resistance genes of breast cancer patients-an overview[J]. Adv Pharm Bull, 2022, 12(4): 649-657.
|
[19] |
ZHANG Y S, YANG C, HAN L, et al. Expression of BCRP/ABCG2 protein in invasive breast cancer and response to neoadjuvant chemotherapy[J]. Oncol Res Treat, 2022, 45(3): 94-101. doi: 10.1159/000520871
|
[20] |
FAN Y F, ZHANG W, ZENG L L, et al. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters[J]. Cancer Lett, 2018, 421: 186-198. doi: 10.1016/j.canlet.2018.01.021
|
[21] |
JI N, YANG Y Q, CAI C Y, et al. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1-and ABCG2-overexpressing cancer cells[J]. Cancer Lett, 2019, 440: 82-93.
|
[22] |
GUPTA P, ZHANG Y K, ZHANG X Y, et al. Voruciclib, a potent CDK4/6 inhibitor, antagonizes ABCB1 and ABCG2-mediated multi-drug resistance in cancer cells[J]. Cell Physiol Biochem, 2018, 45(4): 1515-1528. doi: 10.1159/000487578
|
[23] |
BUKOWSKI K, KCIUK M, KONTEK R. Mechanisms of multidrug resistance in cancer chemotherapy[J]. Int J Mol Sci, 2020, 21(9): 3233. doi: 10.3390/ijms21093233
|
[24] |
DE LUCA A, PARKER L J, ANG W H, et al. A structure-based mechanism of cisplatin resistance mediated by glutathione transferase P1-1[J]. Proc Natl Acad Sci U S A, 2019, 116(28): 13943-13951. doi: 10.1073/pnas.1903297116
|
[25] |
王亚琪, 曾普华, 郜文辉, 等. 益气化瘀解毒方对MRP、GST-π和Topo Ⅱ基因在Sorafenib获得性耐药人肝癌QGY7702细胞表达的干预研究[J]. 吉林中医药, 2020, 40(4): 505-509.WANG Y Q, ZENG P H, GAO W H, et al. Intervention study of Yiqi Huayu Jiedu Prescription on the expression of MRP, GST-π and Topo Ⅱ genes in sorafenib acquired resistant human hepatocellular carcinoma QGY7702 cells[J]. Jilin Journal of Chinese Medicine, 2020, 40(4): 505-509.
|
[26] |
LAU T Y, KWAN H Y. Fucoxanthin is a potential therapeutic agent for the treatment of breast cancer[J]. Mar Drugs, 2022, 20(6): 370. doi: 10.3390/md20060370
|
[27] |
EID S Y, ALTHUBITI M A, ABDALLAH M E, et al. The carotenoid fucoxanthin can sensitize multidrug resistant cancer cells to doxorubicin via induction of apoptosis, inhibition of multidrug resistance proteins and metabolic enzymes[J]. Phytomedicine, 2020, 77: 153280. DOI: 10.1016/j.phymed.2020.153280.
|
[28] |
MCKIE S J, NEUMAN K C, MAXWELL A. DNA topoisomerases: advances in understanding of cellular roles and multi-protein complexes via structure-function analysis[J]. Bioessays, 2021, 43(4): e2000286. DOI: 10.1002/bies.202000286.
|
[29] |
SUNDOV D, MISE B P, MRKLIC I, et al. Prognostic significance of MAPK, Topo Ⅱα and E-cadherin immunoexpression in ovarian serous carcinomas[J]. Neoplasma, 2017, 64(2): 289-298. doi: 10.4149/neo_2017_217
|
[30] |
MANVILLE C M, SMITH K, SONDKA Z, et al. Genome-wide ChIP-seq analysis of human TOP2B occupancy in MCF7 breast cancer epithelial cells[J]. Open Biol, 2015, 4(11): 1436-1447. doi: 10.1242/bio.014308
|
[31] |
MATIAS-BARRIOS V M, RADAEVA M, SONG Y, et al. Discovery of new catalytic topoisomerase Ⅱ inhibitors for anticancer therapeutics[J]. Front Oncol, 2021, 10: 633142. DOI: 10.3389/fonc.2020.633142.
|
[32] |
沙新海, 邢广琳, 黄强. 补骨脂素对乳腺癌干细胞的毒性作用及Topo Ⅱ α基因mRNA和蛋白表达水平的影响[J]. 临床和实验医学杂志, 2019, 18(22): 2397-2400. doi: 10.3969/j.issn.1671-4695.2019.22.012SHA X H, XING G L, HUANG Q. Toxic effects of psoralen on breast cancer stem cells and its influence on TopoⅡα gene m RNA and protein expression level[J]. Journal of Clinical and Experimental Medicine, 2019, 18(22): 2397-2400. doi: 10.3969/j.issn.1671-4695.2019.22.012
|
[33] |
CAI P F, OTTEN A B C, CHENG B B, et al. A genome-wide long noncoding RNA CRISPRi screen identifies PRANCR as a novel regulator of epidermal homeostasis[J]. Genome Res, 2020, 30(1): 22-34. doi: 10.1101/gr.251561.119
|
[34] |
HUANG Q Y, LIU G F, QIAN X L, et al. Long non-coding RNA: dual effects on breast cancer metastasis and clinical applications[J]. Cancers(Basel), 2019, 11(11): 1802.
|
[35] |
QIAO Y, WANG B, YAN Y, et al. Long noncoding RNA ST8SIA6-AS1 promotes cell proliferation and metastasis in triple-negative breast cancer by targeting miR-145-5p/CDCA3 to inactivate the p53/p21 signaling pathway[J]. Environ Toxicol, 2022, 37(10): 2398-2411. doi: 10.1002/tox.23605
|
[36] |
ZHANG X H, LI F Y, ZHOU Y D, et al. Long noncoding RNA AFAP1-AS1 promotes tumor progression and invasion by regulating the miR-2110/Sp1 axis in triple-negative breast cancer[J]. Cell Death Dis, 2021, 12(7): 627. doi: 10.1038/s41419-021-03917-z
|
[37] |
WU J J, XU W, MA L N, et al. Formononetin relieves the facilitating effect of lncRNA AFAP1-AS1-miR-195/miR-545 axis on progression and chemo-resistance of triple-negative breast cancer[J]. Aging (Albany NY), 2021, 13(14): 18191-18222.
|
[38] |
张娜娜. Caspase-3和Bcl-2表达与乳腺癌细胞凋亡及其临床病理特征的相关性分析[J]. 实用癌症杂志, 2021, 36(10): 1609-1613. doi: 10.3969/j.issn.1001-5930.2021.10.011ZHANG N N. Correlation analysis of Caspase-3 and Bcl-2 expression with breast cancer cell apoptosis and its clinicopathological characteristics[J]. The Practical Journal of Cancer, 2021, 36(10): 1609-1613. doi: 10.3969/j.issn.1001-5930.2021.10.011
|
[39] |
杨春梅, 崔晓博, 罗强, 等. 姜黄素逆转耐药作用与Caspase-3关系研究[J]. 实用医学杂志, 2012, 28(3): 355-357. doi: 10.3969/j.issn.1006-5725.2012.03.005YANG C M, CUI X B, LUO Q, et al. Relationship between curcumin resistance reversal and Caspase-3[J]. The Journal of Practical Medicine, 2012, 28(3): 355-357. doi: 10.3969/j.issn.1006-5725.2012.03.005
|